Study Condition(s): Sjogrens Syndrome

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

Study Alias: SSAD

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02614716 {{ currentLocaleObject.registryAnchorText }}

Recruiting Recruiting

Study Purpose

The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18 years
65 years

Time Commitment

Your participation could last up to 28 weeks and include 10 visits to the study center
  • Participant must have a confirmed diagnosis of Sjögren's Syndrome

  • Participant is seropositive for auto-antibodies associated with SS (anti-SSA or anti-SSB) at screening, or documented within 6 months prior to screening

  • Participant must not be currently enrolled in a clinical trial involving an investigational product or off-label use of a drug

  • Participant must not have taken Etanercept, adalimumab, or anakinra <4 weeks before entering the study

  • Participant must not have taken Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab <8 weeks before entering the study

  • Participant must not have taken Rituximab, belimumab or other leukocyte depleting agent <12 months before entering the study

Where to Participate

7 locations are currently available of 7 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.